Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,241 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar TherapeuticsINDUSTRY | 17 | Apr 21, 2023 | clinicaltrials |
| NCT03458221 | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER(STAPOVER) | recruiting | Phase 2 / Phase 3 | 148 | Gynaecologisch Oncologisch Centrum ZuidOTHER |
| 1 |
| Apr 18, 2023 |
| clinicaltrials |
| NCT02756611 | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)(VENICE I) | completed | Phase 3 | 258 | AbbVieINDUSTRY | 21 | Apr 10, 2023 | clinicaltrials |
| NCT00005585 | Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | completed | Phase 3 | 838 | Children's Oncology GroupNETWORK | 6 | Apr 6, 2023 | clinicaltrials |
| NCT00005596 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 1,076 | Children's Oncology GroupNETWORK | 6 | Apr 6, 2023 | clinicaltrials |
| NCT02617589 | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate 498) | completed | Phase 3 | 560 | Bristol-Myers SquibbINDUSTRY | 19 | Mar 28, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT04735432 | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis(ADAPTsc) | completed | Phase 3 | 110 | argenxINDUSTRY | 11 | Feb 28, 2023 | clinicaltrials |
| NCT00301457 | Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer(DATA) | completed | Phase 3 | 1,914 | Maastricht University Medical CenterOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | terminated | Phase 3 | 52 | Goethe UniversityOTHER | 2 | Feb 16, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT01721876 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | completed | Phase 3 | 666 | Boehringer IngelheimINDUSTRY | 25 | Feb 8, 2023 | clinicaltrials |
| NCT02538666 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy(CheckMate 451) | completed | Phase 3 | 907 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 5, 2023 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
| NCT01642004 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) | completed | Phase 3 | 272 | Bristol-Myers SquibbINDUSTRY | 21 | Dec 28, 2022 | clinicaltrials |
| NCT03084471 | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.(STRONG) | completed | Phase 3 | 867 | AstraZenecaINDUSTRY | 8 | Dec 22, 2022 | clinicaltrials |
| NCT02703272 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | terminated | Phase 3 | 72 | Janssen Research & Development, LLCINDUSTRY | 20 | Dec 2, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies(INVICTUS) | completed | Phase 3 | 129 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Nov 21, 2022 | clinicaltrials |
| NCT00433589 | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes(MINDACT) | completed | Phase 3 | 6,600 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Nov 17, 2022 | clinicaltrials |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients(BRAVO) | terminated | Phase 3 | 216 | Tesaro, Inc.INDUSTRY | 14 | Nov 15, 2022 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | terminated | Phase 3 | 481 | Idera Pharmaceuticals, Inc.INDUSTRY | 11 | Nov 8, 2022 | clinicaltrials |
| NCT03590119 | Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases(LUTIA) | completed | Phase 2 / Phase 3 | 26 | Marnix LamOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01057069 | Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer(neo-TN) | active not recruiting | Phase 2 / Phase 3 | 310 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01646034 | High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer(Oligo) | active not recruiting | Phase 3 | 74 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03465722 | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | completed | Phase 3 | 476 | Blueprint Medicines CorporationINDUSTRY | 18 | Oct 6, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT02544763 | A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) | completed | Phase 3 | 224 | Jazz PharmaceuticalsINDUSTRY | 6 | Sep 28, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT01080391 | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | completed | Phase 3 | 792 | AmgenINDUSTRY | 20 | Sep 21, 2022 | clinicaltrials |
| NCT03273153 | A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | terminated | Phase 3 | 446 | Hoffmann-La RocheINDUSTRY | 15 | Sep 21, 2022 | clinicaltrials |
| NCT04389086 | Induction Chemotherapy for Locally Recurrent Rectal Cancer(PelvEx II) | recruiting | Phase 3 | 364 | Catharina Ziekenhuis EindhovenOTHER | 5 | Sep 6, 2022 | clinicaltrials |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy(SANDPIPER) | terminated | Phase 3 | 631 | Hoffmann-La RocheINDUSTRY | 28 | Jul 12, 2022 | clinicaltrials |
| NCT02683941 | Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours(SPINET) | terminated | Phase 3 | 77 | IpsenINDUSTRY | 11 | Jul 6, 2022 | clinicaltrials |
| NCT02714218 | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | completed | Phase 3 | 387 | Bristol-Myers SquibbINDUSTRY | 13 | Jun 24, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 3 | 361 | Hoffmann-La RocheINDUSTRY | 14 | Jun 21, 2022 | clinicaltrials |
| NCT00006455 | Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)(ALCL 99) | completed | Phase 3 | 885 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 10 | May 31, 2022 | clinicaltrials |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer(HATCY) | terminated | Phase 3 | 63 | Kiadis PharmaINDUSTRY | 13 | May 24, 2022 | clinicaltrials |
| NCT02371369 | Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)(ENLIVEN) | completed | Phase 3 | 120 | Daiichi SankyoINDUSTRY | 12 | May 11, 2022 | clinicaltrials |
| NCT01880359 | AF CRT +/- Nimorazole in HNSCC | unknown | Phase 3 | 640 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | May 10, 2022 | clinicaltrials |
| NCT01689519 | A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma(coBRIM) | completed | Phase 3 | 495 | Hoffmann-La RocheINDUSTRY | 19 | May 2, 2022 | clinicaltrials |
| NCT01721746 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | completed | Phase 3 | 405 | Bristol-Myers SquibbINDUSTRY | 14 | Apr 19, 2022 | clinicaltrials |
| NCT03295565 | Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel(OSTRICh) | completed | Phase 2 / Phase 3 | 100 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00376844 | External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer(PORTEC-2) | completed | Phase 3 | 427 | Leiden UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT00687986 | Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer(ROSEL) | terminated | Phase 3 | 22 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 17, 2022 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials